KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dynavax Technologies (DVAX) Current Deferred Revenue: 2009-2022

Historic Current Deferred Revenue for Dynavax Technologies (DVAX) over the last 8 years, with Sep 2022 value amounting to $87.4 million.

  • Dynavax Technologies' Current Deferred Revenue fell 75.63% to $87.4 million in Q3 2022 from the same period last year, while for Sep 2022 it was $87.4 million, marking a year-over-year decrease of 75.63%. This contributed to the annual value of $349.9 million for FY2021, which is 815.59% up from last year.
  • Latest data reveals that Dynavax Technologies reported Current Deferred Revenue of $87.4 million as of Q3 2022, which was down 54.48% from $192.0 million recorded in Q2 2022.
  • Dynavax Technologies' 5-year Current Deferred Revenue high stood at $358.6 million for Q3 2021, and its period low was $21.7 million during Q3 2020.
  • Its 3-year average for Current Deferred Revenue is $171.4 million, with a median of $129.6 million in 2021.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first soared by 1,551.57% in 2021, then tumbled by 75.63% in 2022.
  • Dynavax Technologies' Current Deferred Revenue (Quarterly) stood at $38.2 million in 2020, then surged by 815.59% to $349.9 million in 2021, then tumbled by 75.63% to $87.4 million in 2022.
  • Its Current Deferred Revenue stands at $87.4 million for Q3 2022, versus $192.0 million for Q2 2022 and $313.2 million for Q1 2022.